Bei der Aktie InnoMedica Holding AG (Valor: 55.897.390; ISIN: CH0558973902) handelt es sich um eine Namensaktie, welche elektronisch in das jeweilige Depot der Aktionärin respektive des Aktionärs eingebucht wird. Die InnoMedica-Aktie ist ein nicht börsenkotierter, frei handelbarer Titel. Es sind 19’053’034 Aktien ausstehend (à Nominalwert CHF 0.10). Da es sich um eine Namensaktie handelt, muss eine Eintragung im Aktienregister erfolgen, damit die Aktionärin oder der Aktionär die Stimmrechte der Aktien wahrnehmen kann. Hierfür muss die Inhaberin respektive der Inhaber der Bank eine Ermächtigung erteilen. Je nach Bank ist dies bei jedem Aktienzukauf erneut nötig.

Aktien können in einer Kapitalerhöhung gezeichnet werden, wobei das Investment InnoMedica erlaubt, die angestrebten Fortschritte der Projekte zu realisieren. InnoMedica führt seit 2013 jährlich Kapitalerhöhungen durch, die das Aktionariat auf rund 1’600 Aktionärinnen und Aktionäre ausgeweitet haben und insgesamt CHF 89 Mio. Kapital beschafften. In der Regel wurden die Kapitalerhöhungen im April/Mai durchgeführt. Durch die Einreichung des ausgefüllten Zeichnungsscheins und die Einzahlung des entsprechenden Betrags wird die Aktienzeichnung bei der Zuteilung nach Abschluss der Kapitalerhöhung berücksichtigt. Hierbei gilt jeweils eine in der Kapitalerhöhung festgesetzte Mindestzeichnung, die es einzuhalten gilt.

Outside of the capital increases, InnoMedica offers interested buyers the opportunity to place a purchase request as part of OTC trading. If a matching is possible within the scope of the desired investment, InnoMedica will support the processing of the share purchase, in which case an expense allowance will be charged. In the case of such a purchase, the amount paid does not flow into the company.

InnoMedica offers shareholders who do not have their own bank custody account the opportunity to hold their shares directly with the company. This service has so far been provided free of charge. InnoMedica issues a confirmation of the current shareholding at the end of the year and in the event of changes to the shareholding. Shareholders are obliged to report any changes to their personal details directly.

For unlisted companies without income, the tax value is calculated on the net asset value (gross), whereby a flat-rate deduction of 30% is applied (net). This value is significantly lower than the share value, as the latter takes into account the forecast development of the company. As no revised financial statements are available as at 31 December, this is based on the net asset value of the previous year.

Hauptaktionäre von InnoMedica sind die Familien Halbherr, Yamazaki, Früh und Bron. In einem Aktionärspool zusammengeschlossen kontrollieren sie gemeinsam einen Aktienanteil von 30.2% des Unternehmens.

Regardless of the company, an IPO must always be assessed in the context of the economic situation. In the biotech sector, in particular, companies with a stock market listing have recently had to show patience and have found themselves exposed to extremely unfavorable circumstances. The number of IPOs has plummeted. However, the market situation is not the only condition that must be met for an IPO. If the following conditions are also met, InnoMedica plans to go public:

• Risk profile: A stock exchange listing will substantially expand InnoMedica's shareholder base. The large number of Swiss and foreign shareholders and the participation of institutional investors place increased demands on stability, performance, and profitability. The fulfillment of these criteria is accordingly rewarded with a higher company valuation. InnoMedica believes that it will only fulfil these expectations once it has achieved increasing revenues of at least CHF 10 million per year. In addition, initial sales abroad should also have been realized, possibly supplemented by contracts with distributors or licensing agreements.
  
• Reporting: The high transparency requirements of the stock exchange are a valuable disciplinary element for corporations. InnoMedica already fulfils these requirements to a large extent with the annual documentation for the capital increase and accounting in accordance with international accounting standards.
  
• Costs: A stock market listing involves considerable administrative and financial expenditure. If possible, these expenses should be paid from initial operating income and not from the risk capital of early investors.
  
• Lead partner: A positive share price performance is central to the success of the listing project. InnoMedica negotiates with the key investors and the lead bank to create a solid financial starting position in the run-up to the listing.

InnoMedica prepares the annual report for the previous year in the first half of each year and makes it available to shareholders in electronic and physical form. As a result of the capital increases carried out annually to date, InnoMedica prepares a business plan that informs investors and interested parties about milestones already achieved and upcoming milestones. Information is also provided on the financial planning and the next steps, provided that the capital increase is fully subscribed. InnoMedica also informs shareholders about relevant milestones for achieving the company's goals via the newsletter.